Renata PLC (DSE:RENATA)

Market Cap	56.05B
Revenue (ttm)	41.39B
Net Income (ttm)	2.81B
Shares Out	114.70M
EPS (ttm)	24.53
PE Ratio	19.92
Forward PE	22.42
Dividend	9.20 (1.88%)
Ex-Dividend Date	Oct 22, 2024

Volume	33,550
Average Volume	15,236
Open	493.00
Previous Close	490.90
Day's Range	487.20 - 493.20
52-Week Range	470.10 - 825.00
Beta	0.01
RSI	53.39
Earnings Date	Oct 9, 2025

About Renata

Renata PLC manufactures, markets, and distributes human pharmaceuticals, animal health medicines, nutritionals, and vaccines in Bangladesh. Its pharmaceutical products include antimicrobials, anti-hypertensive, anti-angina, anti-diabetic, eye-ear and topical preparation, antigout, NSAID, anti-spasmodic, steroid, anti-osteoporotic, anti-allergic, cardiovascular, CNS, hormone, anti-cancer, oxytocic, anti-fibrinolytic, anti-asthma, expectorant, oral rehydration saline, narcotic analgesic, antipyretic/analgesic, antiemetic, anesthetic, antiviral, a...

• Industry: Pharmaceutical Preparations
• Founded: 1972
• Employees: 7,859
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: RENATA

Financial Performance

In 2024, Renata's revenue was 37.71 billion, an increase of 14.37% compared to the previous year's 32.97 billion. Earnings were 3.62 billion, an increase of 54.57%.